Published in BJU Int on January 05, 2012
Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis. J Urol (2014) 1.58
Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. Oncotarget (2016) 1.44
Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol (2015) 1.42
Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am J Pathol (2013) 1.16
Adenocarcinoma of the urinary bladder. Am J Clin Exp Urol (2015) 1.04
Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget (2014) 1.03
Role of oestrogen receptors in bladder cancer development. Nat Rev Urol (2013) 1.00
Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer (2012) 1.00
Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. Oncotarget (2014) 1.00
ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression. Oncotarget (2015) 0.96
Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor. Int J Oncol (2012) 0.95
Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol (2013) 0.94
GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res (2014) 0.93
Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms? Int J Mol Sci (2013) 0.86
Fibroblast ERα promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment. Am J Cancer Res (2015) 0.85
Estrogen receptor-β expression and pharmacological targeting in bladder cancer. Oncol Rep (2013) 0.83
Prognostic value of sex-hormone receptor expression in non-muscle-invasive bladder cancer. Yonsei Med J (2014) 0.83
Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression. Am J Clin Pathol (2014) 0.83
The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. World J Urol (2013) 0.81
Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen. Transl Oncol (2013) 0.81
Bladder cancer: a simple model becomes complex. Curr Genomics (2012) 0.81
ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion. Oncotarget (2016) 0.81
Loss of GATA3 in bladder cancer promotes cell migration and invasion. Cancer Biol Ther (2014) 0.80
Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. Cancer Biol Ther (2016) 0.80
Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor. Dis Markers (2015) 0.80
Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer. Int J Clin Exp Pathol (2015) 0.79
Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer (2016) 0.78
Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells. Oncol Rep (2015) 0.77
Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice. PLoS One (2016) 0.76
Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals. Oncotarget (2016) 0.76
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
Female with bladder cancer: what and why is there a difference? Transl Androl Urol (2016) 0.75
High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. Transl Oncol (2017) 0.75
The effects of early versus delayed castration targeting androgen on prolonging survival in a mouse model of bladder cancer. Int J Clin Exp Pathol (2015) 0.75
Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer. Oncotarget (2016) 0.75
Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother (2016) 0.75
Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. Oncotarget (2016) 0.75
NFATc1 Expression as a Prognosticator in Urothelial Carcinoma of the Upper Urinary Tract. Transl Oncol (2017) 0.75
Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies. PLoS One (2017) 0.75
Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer. Oncotarget (2016) 0.75
Androgen Receptor Signaling in Bladder Cancer. Cancers (Basel) (2017) 0.75
Current clinical trials in non-muscle invasive bladder cancer. Urol Oncol (2017) 0.75
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Androgen receptor (AR) coregulators: an overview. Endocr Rev (2002) 4.01
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer (2011) 3.54
Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J (2002) 3.27
Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A (2002) 3.08
Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer (2012) 2.98
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Growth retardation and abnormal maternal behavior in mice lacking testicular orphan nuclear receptor 4. Proc Natl Acad Sci U S A (2004) 2.78
Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst (2007) 2.59
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47
Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells. Proc Natl Acad Sci U S A (2004) 2.41
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology (2008) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol (2011) 2.20
Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology (2009) 2.18
The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol (2002) 2.12
Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate (2004) 1.96
Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A (2007) 1.93
Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem (2003) 1.90
Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol (2003) 1.89
A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol (2010) 1.87
ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med (2007) 1.87
Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol (2012) 1.85
Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med (2010) 1.84
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK. Nat Chem Biol (2012) 1.75
Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int (2010) 1.69
Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem (2001) 1.69
Androgen receptor in sertoli cell is essential for germ cell nursery and junctional complex formation in mouse testes. Endocrinology (2006) 1.69
Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl (2007) 1.67
Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci U S A (2008) 1.65
Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol (2004) 1.62
Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest (2009) 1.62
Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer (2011) 1.62
Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J Biol Chem (2002) 1.62
TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol (2009) 1.61
Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol (2008) 1.60
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol (2011) 1.58
VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep (2005) 1.57
Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem (2002) 1.57
Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun (2002) 1.56
Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. Endocr Rev (2009) 1.55
Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors. Hum Pathol (2013) 1.54
ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol (2011) 1.54
A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol (2005) 1.54
Pseudoglandular (adenoid, acantholytic) penile squamous cell carcinoma: a clinicopathologic and outcome study of 7 patients. Am J Surg Pathol (2009) 1.51
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res (2009) 1.51
Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. BJU Int (2008) 1.48
Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol (2002) 1.48
Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem (2005) 1.46
Complications associated with extraperitoneal robot-assisted radical prostatectomy using the standardized Martin classification. Urology (2013) 1.44
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res (2013) 1.43
Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med (2003) 1.42
Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol (2004) 1.41
Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens. Mod Pathol (2011) 1.41
Bladder tumor markers. J Urol (2006) 1.40
Recent advances in the TR2 and TR4 orphan receptors of the nuclear receptor superfamily. J Steroid Biochem Mol Biol (2002) 1.39
TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res (2013) 1.39
Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci U S A (2004) 1.39
Loss of TR4 orphan nuclear receptor reduces phosphoenolpyruvate carboxykinase-mediated gluconeogenesis. Diabetes (2007) 1.39
Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol (2010) 1.39
An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res (2011) 1.37
Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun (2003) 1.36
Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol (2012) 1.35
NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol (2009) 1.35
Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol (2013) 1.35
TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation. Proc Natl Acad Sci U S A (2009) 1.33
Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes (2005) 1.33
Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology (2008) 1.32
Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate (2006) 1.32
Deficits in motor coordination with aberrant cerebellar development in mice lacking testicular orphan nuclear receptor 4. Mol Cell Biol (2005) 1.31